RxDoctor Payments Data

Dulce Almanzar, MD

Family Medicine · Bay Shore, NYNPI 1760458715

Payments from drug & device makers

$1,566in general payments, 2019–2025

Across 52 payments — averaging $30.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$318
  • Exact Sciences$229
  • Abbott$179
  • Astellas Pharma US Inc$170
  • Daiichi Sankyo Inc.$155
  • Novo Nordisk$136
  • plus $379 from 8 others

What the payments were for

  • Food & beverage$1,566100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,566 in reported general payments places this provider in the 70th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$80,100
Medicare patients
126
Services billed
1,720

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide161$147,026
MounjaroTirzepatide101$112,443
JanuviaSitagliptin Phosphate42$43,031
JardianceEmpagliflozin19$24,263
EliquisApixaban18$22,353
FarxigaDapagliflozin Propanediol28$21,778
JanumetSitagliptin Phos/Metformin Hcl18$18,837
LinzessLinaclotide19$17,209
XareltoRivaroxaban15$15,716
RybelsusSemaglutide11$13,227
TrulicityDulaglutide11$10,977
VascepaIcosapent Ethyl21$9,956
Omega-3 Acid Ethyl Esters87$5,749
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$4,779
Albuterol Sulfate HfaAlbuterol Sulfate110$4,007

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$136$160,253172 claims
PfizerEliquis$39$22,35318 claims
AbbVieLinzess$16$17,20919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,321 family medicine providers in New York.

Other family medicine in Bay Shore

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →